Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD

International Journal of Chronic Obstructive Pulmonary Disease
C JansonKjell Larsson

Abstract

Inhaled corticosteroids (ICSs) treatment combined with long-acting β2-adrenoceptor agonists (LABAs) reduces the risk of exacerbations in COPD, but the use of ICSs is associated with increased incidence of pneumonia. There are indications that this association is stronger for fluticasone propionate than for budesonide. We have examined systematic reviews assessing the risk of pneumonia associated with fluticasone propionate and budesonide COPD therapy. Compared with placebo or LABAs, we found that fluticasone propionate was associated with 43%-78% increased risk of pneumonia, while only slightly increased risk or no risk was found for budesonide. We have evaluated conceivable mechanisms which may explain this difference and suggest that the higher pneumonia risk with fluticasone propionate treatment is caused by greater and more protracted immunosuppressive effects locally in the airways/lungs. These effects are due to the much slower dissolution of fluticasone propionate particles in airway luminal fluid, resulting in a slower uptake into the airway tissue and a much longer presence of fluticasone propionate in airway epithelial lining fluid.

Citations

Mar 6, 2018·Expert Opinion on Drug Safety·Maria Gabriella MateraMario Cazzola
Jun 21, 2018·Respirology : Official Journal of the Asian Pacific Society of Respirology·Jose Luis Lopez-CamposEsther Barreiro
Aug 14, 2018·Expert Review of Cardiovascular Therapy·J Alberto NederDenis E O'Donnell
Sep 25, 2019·Drugs·Donald P TashkinRalph Brattsand
Jan 28, 2020·Journal of Comparative Effectiveness Research·Douglas W MapelJill Davis
Sep 23, 2020·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Dani Do Hyang LeeChristopher O'Callaghan
Dec 19, 2019·Pharmacological Reviews·M G MateraM Cazzola
Apr 16, 2019·Expert Opinion on Pharmacotherapy·Chitra Lal, Charlie Strange
Nov 6, 2020·International Journal of Chronic Obstructive Pulmonary Disease·Andriana I PapaioannouNikos Tzanakis
Jan 7, 2021·International Journal of Chronic Obstructive Pulmonary Disease·Ji-Ho LeeWon-Yeon Lee
Jul 25, 2020·The European Respiratory Journal·Tetyana KendzerskaUNKNOWN Canadian Respiratory Research Network and CanBREATHE (the Canadian Best Respiratory Research Evaluation and Analyst Team of
Nov 19, 2020·International Journal of Chronic Obstructive Pulmonary Disease·Thomas P LodiseSanjay Sethi
Mar 19, 2021·Biochemistry and Biophysics Reports·Kensuke YasudaKazuichi Sakamoto
Dec 1, 2019·Respiratory Medicine·Hung-Ling HuangInn-Wen Chong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.